Overview
Through a scientific and standardized multicenter, blinding, double-dummy, randomized controlled, noninferiority clinical trial study method, the investigators evaluated electroacupuncture as a safe and effective non-pharmacological treatment for OAB in women by comparison with Solifenacin Succinate.
Description
Epidemiological researches have shown that approximately 500 million people worldwide are affected by OAB, 2 3 with a higher incidence in women than that in men. Pharmacological treatment remains the usual method of clinical treatment. However, some Pharmacologphy has certain side effects, such as blurred consciousness, dry mouth, constipation, and so on, which have limited its widespread clinical use. Therefore, the treatment of OAB needs comprehensive consideration in clinical practice, which deserves our attention and active exploration of other effective treatment methods to relieve patients' pain.Electroacupuncture can effectively improve the clinical symptoms of OAB. As for the comparison between electroacupuncture and medication for the treatment of OAB in women, the results are inconclusive based on the limited research evidence. The aim of the study is to investigate the effectiveness and safety of electroacupuncture compared to Solifenacin Succinate.
Eligibility
Inclusion Criteria:
- Meet the American Urological Association (AUA) diagnostic criteria for adult overactive bladder disorder (non-neurogenic) and the Chinese Urological Association's Guidelines for the Diagnosis and Treatment of Urological Diseases in China (2014 edition) for OAB.
- Female patients aged 18-75 years.
- Duration of illness with OAB ≥ 3 months.
- 3≤OABSS≤11.
- No abnormality in routine urine tests.
- Patients had never received acupuncture treatment.
- No mental or intellectual abnormalities, able to understand the provisions of the scales and complete the assessment.
- Consent to participate in this study and sign a written informed consent.
Exclusion Criteria:
- Combination of more serious heart, liver, kidney and other serious diseases; Or patients with severe liver or kidney insufficiency.
- Patients with pelvic organ prolapse ≥ Ⅱ degree, urinary system surgery history or pelvic floor surgery history.
- Patients with other diseases presenting with OAB symptoms.
- Those with urinary diseases (such as calculi and tuberculosis of the bladder), malignant tumors, and neurological disorders.
- Patients who are pregnant or breastfeeding.
- Patients using medication that may affect bladder function one month prior to enrollment or having received behavioural therapy for OAB three months prior to enrolment, etc.
- Patients with pacemakers.
- Patients with blood diseases, diabetes mellitus or mental diseases.
- Infections, ulcers, abscesses, and skin infections at needling sites; metal allergy or extreme needle phobia.
- Participation in other clinical medical trial studies over the last month.